Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-001 in Hospitalized Patients With Pneumonia
NCT05123755Phase 2Active, not recruiting
- Sponsor
- Vasomune Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pneumonia, coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing AV-001 Injection with Placebo (2 arms). Primary endpoint: Safety and tolerability of multiple doses of IV administrations. Started Dec 2021; status: active, not recruiting.
02
Drugs
pegevongitide
03
Conditions
pneumoniacoronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05123755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123755.